Abstract
An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.
©2013 AACR.
Publication types
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
CD40 Antigens / agonists*
-
Carcinoma, Pancreatic Ductal / drug therapy*
-
Female
-
Humans
-
Male
-
Pancreatic Neoplasms / drug therapy*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
CD40 Antigens
-
selicrelumab